Sign in or create an account to add this stock to your watchlist.
About AtriCure (NASDAQ:ATRC)
AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. AtriCure sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ATRC
CUSIP04963C20
Phone513-755-4100
Debt
Debt-to-Equity Ratio0.34
Current Ratio3.15
Quick Ratio2.31
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$174.72 million
Price / Sales4.85
Cash FlowN/A
Price / CashN/A
Book Value$4.37 per share
Price / Book5.53
Profitability
EPS (Most Recent Fiscal Year)($0.83)
Net Income$-26,890,000.00
Net Margins-14.88%
Return on Equity-16.92%
Return on Assets-9.99%
Miscellaneous
Employees570
Outstanding Shares35,040,000
AtriCure (NASDAQ:ATRC) Frequently Asked Questions
What is AtriCure's stock symbol?
AtriCure trades on the NASDAQ under the ticker symbol "ATRC."
How were AtriCure's earnings last quarter?
AtriCure (NASDAQ:ATRC) announced its earnings results on Thursday, April, 26th. The medical device company reported ($0.31) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.27) by $0.04. The medical device company earned $46.99 million during the quarter, compared to analyst estimates of $45.43 million. AtriCure had a negative net margin of 14.88% and a negative return on equity of 16.92%. The business's quarterly revenue was up 13.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.32) earnings per share. View AtriCure's Earnings History.
When is AtriCure's next earnings date?
What price target have analysts set for ATRC?
5 brokers have issued 12-month price objectives for AtriCure's stock. Their forecasts range from $23.00 to $26.00. On average, they anticipate AtriCure's share price to reach $25.00 in the next twelve months. View Analyst Ratings for AtriCure.
What are Wall Street analysts saying about AtriCure stock?
Here are some recent quotes from research analysts about AtriCure stock:
- 1. According to Zacks Investment Research, "AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart. " (5/2/2018)
- 2. Needham & Company LLC analysts commented, "ATRC’s 4Q17 revenue was consistent with its 1/8/18 preannouncement while its EBITDA missed consensus and EPS beat consensus even excluding a $0.12 non-cash benefit. Management reiterated its 2018 revenue guidance of $190-196M vs. consensus of $195M. We believe the recent society guidelines, new products (AtriClip Pro-V and Flex-V), and surgeon training activities should drive strong growth. We believe that management’s more conservative guidance leaves room for upside and with ATRC shares trading at a large discount to peers (2018E EV/sales of 3.3x vs. small/mid-cap growth peers at a median of 6.4x), we reiterate our Buy rating." (2/27/2018)
Who are some of AtriCure's key competitors?
Some companies that are related to AtriCure include NovoCure (NVCR), Merit Medical Systems (MMSI), NuVasive (NUVA), Nevro (NVRO), iRhythm (IRTC), Mazor Robotics (MZOR), Glaukos (GKOS), Luminex (LMNX), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), Cardiovascular Systems (CSII), CryoLife (CRY), MiMedx Group (MDXG) and OraSure Technologies (OSUR).
Who are AtriCure's key executives?
AtriCure's management team includes the folowing people:
- Mr. Michael H. Carrel, Chief Exec. Officer, Pres and Director (Age 47)
- Mr. M. Andrew Wade, Chief Financial Officer and Sr. VP (Age 43)
- Mr. Douglas J. Seith, Chief Operating Officer (Age 52)
- Mr. Justin J. Noznesky, Sr. VP of Marketing and Bus. Devel. (Age 40)
- Mr. Karl Dahlquist, Chief Compliance Officer and VP of Legal & Compliance
Has AtriCure been receiving favorable news coverage?
News headlines about ATRC stock have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AtriCure earned a coverage optimism score of 0.06 on Accern's scale. They also assigned media coverage about the medical device company an impact score of 44.36 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are AtriCure's major shareholders?
AtriCure's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.48%), Hudson Executive Capital LP (6.78%), First Light Asset Management LLC (3.33%), Millennium Management LLC (2.45%), Loomis Sayles & Co. L P (2.30%) and Neuberger Berman Group LLC (2.23%). Company insiders that own AtriCure stock include Andrew L Lux, B Kristine Johnson, Elizabeth D Krell, Justin J Noznesky, M Andrew Wade and Regina E Groves. View Institutional Ownership Trends for AtriCure.
Which major investors are selling AtriCure stock?
ATRC stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, BlackRock Inc., GSA Capital Partners LLP, Neuberger Berman Group LLC, Wasatch Advisors Inc., Loomis Sayles & Co. L P, Nuveen Asset Management LLC and A.R.T. Advisors LLC. Company insiders that have sold AtriCure company stock in the last year include Elizabeth D Krell, Justin J Noznesky and M Andrew Wade. View Insider Buying and Selling for AtriCure.
Which major investors are buying AtriCure stock?
ATRC stock was acquired by a variety of institutional investors in the last quarter, including Hudson Executive Capital LP, The Manufacturers Life Insurance Company , Millennium Management LLC, First Light Asset Management LLC, Quantum Capital Management, Tamarack Advisers LP, Trexquant Investment LP and Highbridge Capital Management LLC. Company insiders that have bought AtriCure stock in the last two years include B Kristine Johnson and Regina E Groves. View Insider Buying and Selling for AtriCure.
How do I buy shares of AtriCure?
Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AtriCure's stock price today?
One share of ATRC stock can currently be purchased for approximately $24.16.
How big of a company is AtriCure?
AtriCure has a market capitalization of $835 million and generates $174.72 million in revenue each year. The medical device company earns $-26,890,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. AtriCure employs 570 workers across the globe.
How can I contact AtriCure?
AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.
MarketBeat Community Rating for AtriCure (ATRC)
MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe ATRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRC will underperform the S&P 500 over the long term. You may vote once every thirty days.
AtriCure (NASDAQ:ATRC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for AtriCure in the last 12 months. Their average twelve-month price target is $25.00, suggesting that the stock has a possible upside of 3.48%. The high price target for ATRC is $26.00 and the low price target for ATRC is $23.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 2.86 | 2.86 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $25.00 | $24.80 | $24.3333 | $25.00 |
| Price Target Upside: | 3.48% upside | 35.37% upside | 37.24% upside | 16.60% upside |
AtriCure (NASDAQ:ATRC) Consensus Price Target History
AtriCure (NASDAQ:ATRC) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
AtriCure (NASDAQ:ATRC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
AtriCure (NASDAQ ATRC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 87.56%
AtriCure (NASDAQ ATRC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/8/2018 | Elizabeth D Krell | Director | Sell | 10,000 | $22.82 | $228,200.00 | 29,967 |  |
| 3/13/2018 | Elizabeth D Krell | Director | Sell | 10,000 | $20.00 | $200,000.00 | | |
| 3/1/2018 | Regina E Groves | Director | Buy | 1,000 | $17.43 | $17,430.00 | | |
| 2/15/2018 | Justin J Noznesky | SVP | Sell | 4,000 | $17.03 | $68,120.00 | | |
| 11/30/2017 | M. Andrew Wade | CFO | Sell | 2,000 | $18.41 | $36,820.00 | | |
| 11/8/2017 | B Kristine Johnson | Director | Buy | 1,500 | $18.36 | $27,540.00 | 10,969 | |
| 8/22/2017 | Elizabeth D Krell | Director | Sell | 10,000 | $22.40 | $224,000.00 | 29,967 | |
| 5/17/2017 | Elizabeth D Krell | Director | Sell | 10,000 | $21.44 | $214,400.00 | 24,162 | |
| 3/17/2017 | Andrew L Lux | SVP | Sell | 20,000 | $18.85 | $377,000.00 | 85,589 | |
| 11/15/2016 | Elizabeth D Krell | Director | Sell | 10,000 | $19.73 | $197,300.00 | 24,162 | |
| 9/13/2016 | Elizabeth D Krell | Director | Sell | 6,000 | $15.93 | $95,580.00 | 20,162 | |
| 8/17/2016 | Elizabeth D Krell | Director | Sell | 5,000 | $15.20 | $76,000.00 | 15,162 | |
| 3/8/2016 | Elizabeth D Krell | Director | Sell | 10,000 | $16.91 | $169,100.00 | 17,162 | |
| 12/3/2015 | Douglas J. Seith | COO | Sell | 5,000 | $21.55 | $107,750.00 | 125,215 | |
| 12/2/2015 | Elizabeth D. Krell | Director | Sell | 10,000 | $21.88 | $218,800.00 | 7,162 | |
| 11/11/2015 | Elizabeth D. Krell | Director | Sell | 10,000 | $20.68 | $206,800.00 | 7,162 | |
| 4/1/2015 | Michael D Hooven | Director | Sell | 142,268 | $20.81 | $2,960,597.08 | | |
| 3/31/2015 | Michael D Hooven | Director | Sell | 20,000 | $20.51 | $410,200.00 | | |
| 3/30/2015 | Michael D Hooven | Director | Sell | 85,000 | $21.01 | $1,785,850.00 | | |
| 3/13/2015 | Karen P Robards | Director | Sell | 3,150 | $19.53 | $61,519.50 | | |
| 3/5/2015 | Douglas J Seith | COO | Sell | 36,688 | $17.51 | $642,406.88 | | |
| 3/2/2015 | Elizabeth D Krell | Director | Sell | 10,000 | $17.63 | $176,300.00 | | |
| 5/6/2014 | Douglas Seith | SVP | Buy | 1,000 | $15.04 | $15,040.00 | 95,694 | |
| 9/13/2013 | Richard Johnston | Insider | Sell | 77,610 | $10.00 | $776,100.00 | | |
| 8/12/2013 | Douglas Seith | SVP | Buy | 10,000 | $9.58 | $95,800.00 | 58,240 | |
| 8/5/2013 | Richard Johnston | Insider | Sell | 20,047 | $10.00 | $200,470.00 | | |
| 7/11/2013 | Richard M Johnston | Insider | Sell | 2,343 | $10.00 | $23,430.00 | | |
| 6/19/2013 | Richard M Johnston | Insider | Sell | 29,348 | $8.96 | $262,958.08 | | |
| 6/18/2013 | Richard M Johnston | Insider | Sell | 39,682 | $9.18 | $364,280.76 | | |
| 6/14/2013 | Richard M Johnston | Insider | Sell | 95,598 | $8.97 | $857,514.06 | | |
| 6/12/2013 | Richard M Johnston | Insider | Sell | 35,372 | $9.01 | $318,701.72 | | |
| 3/6/2013 | James L Lucky | VP | Sell | 50,065 | $8.14 | $407,529.10 | | |
| 9/14/2012 | Mark R Lanning | Director | Buy | 11,006 | $7.64 | $84,085.84 | | |
| 9/13/2012 | Michael D Hooven | Director | Buy | 1,110 | $7.37 | $8,180.70 | | |
| 9/12/2012 | Michael D Hooven | Director | Buy | 1,150 | $7.10 | $8,165.00 | | |
| 9/11/2012 | Michael D Hooven | Director | Buy | 1,145 | $7.18 | $8,221.10 | | |
| 9/10/2012 | Michael D Hooven | Director | Buy | 1,215 | $7.15 | $8,687.25 | | |
| 9/7/2012 | Michael D Hooven | Director | Buy | 1,215 | $6.88 | $8,359.20 | | |
| 8/23/2012 | Karen P Robards | Director | Buy | 1,000 | $6.70 | $6,700.00 | | |
| 8/16/2012 | Karen P Robards | Director | Buy | 1,000 | $6.98 | $6,980.00 | | |
(Data available from 1/1/2013 forward)
AtriCure (NASDAQ ATRC) News Headlines
| Source: |
|
AtriCure (NASDAQ:ATRC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
AtriCure (NASDAQ:ATRC) Income Statement, Balance Sheet and Cash Flow Statement
AtriCure (NASDAQ ATRC) Stock Chart for Saturday, May, 26, 2018
Loading chart…
